Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

The coronavirus pandemic is having a big impact on LabCorp, but maybe not in the way you expected.

Why Is Everyone Talking About LabCorp Stock?

Companies will be able to screen their employees for the coronavirus and test them for prior infections with SARS-CoV-2.

LabCorp Launches COVID-19 Testing Service to Help Workers Get Back on the Job

Widespread testing will be critical to boosting the confidence of the public to return to work and to detecting and preventing a resurgence of the virus as states ease restrictions.

LabCorp CEO says the US doesn't need 2 million coronavirus tests per day to reopen

Shares of Laboratory Corporation of America Holdings LH, +0.96% gained 2.1% in premarket trading on Tuesday after the test maker said it had expanded its at-home COVID-19 test to the general public.

LabCorp's stock gains as at-home COVID-19 is expanded to the public

Quest Diagnostics

It's a really close contest between these two diagnostics-testing stocks.

Better Coronavirus Stock: Quest Diagnostics or LabCorp?

A LabCorp shareholder has filed a lawsuit against the laboratory giant, accusing its board of concealing details of two data breaches that affected millions of patients. The derivative suit, filed on Tuesday by shareholder Raymond Eugenio, targets the company’s leadership and board members, including its chief executive Adam Schechter.

LabCorp slapped with shareholder suit over data breaches

Laboratory Corporation of America Holdings (LH) CEO Adam Schechter on Q1 2020 Results - Earnings Call Transcript

LabCorp's (LH) Covance Drug Development revenues improve despite COVID-19 hurdles.

LabCorp's (LH) Q1 Earnings Beat Estimates, Margins Down

The company got off to a strong start in the first quarter but saw a big drop in diagnostic testing in the last two weeks of the quarter due to the coronavirus outbreak.

LabCorp Beats Expectations in Q1 Despite COVID-19 Drag

LabCorp (LH) delivered earnings and revenue surprises of 34.66% and 3.89%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Q1 Earnings and Revenues Beat Estimates

The company said the hit to demand for diagnostic testing was "was marginally offset by an increase in demand for COVID-19 tests."

LabCorp swings to a loss, withdraws 2020 guidance as coronavirus outbreak drives up costs

Laboratory Corporation Of America sees its Relative Strength Rating hit the 80-plus level.
The post Laboratory Corporation Of America Trades Near 52-Week High, Hitting 80-Plus RS Rating appeared first on Investor's Business Daily.

Laboratory Corporation Of America Trades Near 52-Week High, Hitting 80-Plus RS Rating

Align Technology

Boston Scientific

Hologic

Many Medical Product stocks might have succeeded in mitigating coronavirus-led downsides banking on huge market adoption of their COVID-19-related healthcare-support products.

Medical Products Stock Earnings on Apr 29: BSX, ALGN & More

LabCorp (LH) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

LabCorp (LH) Looks Good: Stock Adds 9% in Session

LabCorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: LabCorp (LH) Q1 Earnings Expected to Decline

LabCorp also was granted FDA approval this week for its at-home test for Covid-19.

LabCorp is widening availability of its antibody test to detect exposure to the coronavirus

With supplies currently limited, kits will be prioritized for healthcare workers and first responders, but as production ramps up in coming weeks, they will be made broadly available.

FDA Authorizes LabCorp's At-Home COVID-19 Test Kit

Laboratory Corporation of America Holdings shares were trading higher Tuesday after U.S. health regulators approved the company’s coronavirus test that allows people to collect their own sample at home, according to The Associated Press.

FDA Authorizes First At-Home, Self-Swab Coronavirus Test

LabCorp (LH) is expected to have witnessed a significant fall in its quarterly revenues due to the coronavirus mayhem.

Will LabCorp's (LH) Coronavirus Test Boost Q1 Earnings?

LabCorp’s at-home COVID-19 test, which is called ‘Pixel,’ has received the first Emergency Use Authorization (EUA) for such a test missed by the U.S. Food and Drug Administration (FDA).

LabCorp’s at-home COVID-19 test kit is the first to be authorized by the FDA

Shares of Laboratory Corporation of America Holdings LH, -1.95% gained 5% in premarket trading on Tuesday after the company announced it received an emergency use authorization from the Food and Drug Administration to market an at-home COVID-19 testing kit.

LabCorp's stock rises on EUA for at-home COVID-19 test

Abbott Labs

Roche Holding AG

Thermo Fisher Scientific

Diagnostic laboratories, rather than the test manufacturers, may be the biggest beneficiaries.

Good News for COVID-19 Testing Companies: Medicare Nearly Doubles Reimbursement

If we can test the working population, we will be able to bring the healthy American's back to work and isolate those with the virus

3 Stocks Testing The Coronavirus

Amazon

Salesforce

HCA Healthcare

Microsoft

The private industry coalition will address healthcare resources, testing, and other challenges.

Healthcare, Tech Giants Join Forces to Fight COVID-19

LabCorp's (LH) Covance arm grows on strategic acquisitions including MI Bioresearch.

News for Labcorp Holdings Inc Stock (LH)